Fulvestrant (Faslodex): current status in the therapy of breast cancer.

Article Details

Citation

Copy to clipboard

Bundred N, Howell A

Fulvestrant (Faslodex): current status in the therapy of breast cancer.

Expert Rev Anticancer Ther. 2002 Apr;2(2):151-60.

PubMed ID

12113237 [ View in PubMed

]

Abstract

Fulvestrant (Faslodex, formerly ICI 182,780) is a potent steroidal antiestrogen that mediates its effects by estrogen receptor downregulation. It appears to act as a pure antiestrogen and exhibits none of the negative side effects associated with the partial agonist activity of tamoxifen. It has been shown to be as effective as the oral aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer who have progressed on prior endocrine therapy, principally tamoxifen. It therefore provides the clinician with an alternative therapeutic strategy following the development of tamoxifen resistance. Fulvestrant might also have potential as a follow-on therapy after tamoxifen in an adjuvant setting and help alleviate some of the concerns surrounding long-term (up to 5 years) tamoxifen therapy.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Fulvestrant	Estrogen receptor alpha	Protein	Humans	Yes	Antagonist	Details